TIDMAVO

RNS Number : 4010R

Advanced Oncotherapy PLC

04 November 2021

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Holding(s) in Company

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, has been informed that as a result of the dilution from the Company's recent issue of shares, Nerano Capital Limited's beneficial interest remains as 22,500,000 ordinary shares of 25p each in the Company ("Ordinary Shares") but now represents 4.99% of the Company's issued share capital. Nerano Capital Limited is controlled by Mr Seamus Mulligan who also controls Barrymore Investments Limited which holds 7,905,721 Ordinary Shares, which represents 1.75% of the Company's issued share capital.

 
 Advanced Oncotherapy plc                                                          www.avoplc.com 
 Dr Michael Sinclair, Executive Chairman                                Tel: +44 (0) 20 3617 8728 
 Nicolas Serandour, CEO 
 
 Allenby Capital Limited (Nomad and Joint Broker) 
 Nick Athanas / Liz Kirchner (Corporate Finance)                        Tel: +44 (0) 20 3328 5656 
  Amrit Nahal / Matt Butlin (Sales and Corporate Broking) 
 
 SI Capital Ltd (Joint Broker) 
 Nick Emerson                                                           Tel: +44 (0) 1483 413 500 
 Jon Levinson                                                           Tel: +44 (0) 20 3871 4066 
 
 FTI Consulting (Financial PR & IR)                         advancedoncotherapy@fticonsulting.com 
 Simon Conway / Rob Winder                                              Tel: +44 (0) 20 3727 1000

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLUSSORAUUARAA

(END) Dow Jones Newswires

November 04, 2021 09:44 ET (13:44 GMT)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Advanced Oncotherapy Charts.
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Advanced Oncotherapy Charts.